Overview

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

Status:
Terminated
Trial end date:
2016-08-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test how safe and effective the combination of RAD001 and erlotinib is in patients with neuroendocrine tumors.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Genentech, Inc.
Novartis Pharmaceuticals
The V Foundation for Cancer Research
Treatments:
Erlotinib Hydrochloride
Everolimus
Sirolimus